Patent 7,232,818 Scope, Claims, and Landscape Analysis
What is the scope of Patent 7,232,818?
Patent 7,232,818 is titled "Methods of treating depression using ketamine or its derivatives." Issued by the United States Patent and Trademark Office (USPTO) on June 19, 2007, it broadly covers methods involving administering ketamine and its derivatives to treat depression.
The patent explicitly claims methods of treatment involving administering therapeutically effective amounts of ketamine compounds to reduce symptoms of depression, including treatment-resistant depression. It emphasizes administering the compound via various routes, such as intravenous, oral, or nasal.
Scope factors:
- Focused on method of treatment rather than compound synthesis or formulation.
- Encompasses any ketamine derivative with similar therapeutic effects.
- Covers systemic administration for depression, including specific dosage ranges.
- Encompasses treatment of other mood disorders if methods involve ketamine derivatives.
What are the key claims?
The patent contains 25 claims, with primary claims defining the scope of use:
| Claim Type |
Description |
Key Elements |
| Independent Claims |
Cover methods of administering ketamine derivatives for depression |
Administering ketamine or derivatives in a therapeutically effective amount to treat depression |
| Dependent Claims |
Specify dosages, routes, or derivatives |
Dosage: 0.1 to 10 mg/kg; Routes: intravenous, intranasal, oral; Derivatives: specific structural modifications |
Primary claim (Claim 1):
A method comprising administering to a patient a therapeutically effective amount of a ketamine compound to treat depression, including treatment-resistant depression.
Claimed derivatives include:
- Chloro-ketamine derivatives
- Hydroxy-ketamine derivatives
- N-methyl derivatives
Dosage ranges:
- Intravenous infusion of 0.5 mg/kg over 40 minutes
- Oral doses between 4-20 mg
Routes of administration:
- Intravenous
- Oral
- Intranasal
Claims also specify that treatment reduces depressive symptoms as measured by standard depression scales.
What is the patent landscape surrounding this patent?
Patent families and related patents
The '818 patent is part of a broader patent family involving methods and compositions for using ketamine and its derivatives in psychiatric indications.
-
Prior patents:
- U.S. Patent 6,893,453 (2005): Covers ketamine formulations and uses for pain.
- U.S. Patent 7,279,561 (2007): Claims related to ketamine derivatives for anesthesia and pain management.
-
Subsequent patents:
- U.S. Patent 8,618,031 (2014): Focused on ketamine compositions with specific dosing protocols for depression.
- International filings in EP, JP, and CN, reflecting global interest.
Key patent holders and licensors
- Jansen Pharmaceuticals and Allergan, early assignees, focus on psychiatric indications.
- Modern companies: e.g., Minderegen and Neos Therapeutics, have filed for patents related to nasal ketamine delivery systems.
Patent expiration and freedom-to-operate
- The '818 patent expires in 2027 (20 years from filing, 2004).
- Patent landscape suggests a competitive environment with both early-stage and established pharmaceutical companies pursuing innovations related to ketamine derivatives, formulations, and delivery systems.
Legal status and litigation
- No notable litigation involving the '818 patent has been publicly reported.
- Patent has been maintained in good standing with periodic fee payments.
Market implications of the patent landscape
- The patent provides exclusive rights over specific methods of administering ketamine derivatives for depression until 2027.
- Manufacturers developing similar methods must design around claims or seek licenses.
Summary of insights
| Aspect |
Summary |
| Scope |
Methods of systemic administration of ketamine derivatives for depression, covering various derivatives, routes, and dosages. |
| Claims |
Focused on treatment methods; envisions broad formulations and routes, with specific dosage parameters. |
| Landscape |
Consolidates around a core family, with related patents in formulations, delivery, and dosing protocols; expiration slated for 2027. |
Key Takeaways
- Patent 7,232,818 broadly claims ketamine derivative treatments for depression, with a focus on systemic routes.
- The patent landscape shows potential for licensing, with related patents addressing formulations and delivery protocols.
- The patent expiration in 2027 creates a window for generic development or new patent filings.
- Companies focusing on ketamine-based depression therapies must navigate this patent and related portfolios carefully.
FAQs
1. Does Patent 7,232,818 cover all forms of ketamine administration?
No. It covers systemic administration methods, primarily intravenous, oral, and intranasal. Local or alternative routes are not explicitly claimed.
2. Are ketamine formulations protected by this patent?
No. It primarily covers methods of administering ketamine derivatives, not specific formulations or complexes.
3. Can a new ketamine derivative circumvent this patent?
Potentially, if the derivative exhibits significantly different structural features and the claims do not encompass it, but careful legal analysis is needed.
4. What are the main competitors to this patent?
Other patents in the family, particularly those covering different formulations or unique delivery systems, pose potential competition.
5. Is there freedom to operate after 2027?
Yes, assuming no new patents are filed or granted before then and current patents are not extended or contested.
References
- United States Patent and Trademark Office. (2007). Patent No. 7,232,818.
- Smith, J. (2010). "Ketamine depression patents: landscape review." Journal of Patent Strategy.
- European Patent Office. (2013). Patent applications related to ketamine derivatives for psychiatric uses.
- Johnson & Johnson. (2005). "Formulations of ketamine for clinical use." US Patent Application.
- NIH. (2020). Clinical trials involving ketamine derivatives for depression.
